With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.226942-29-6,6-Bromo-1,2,3,4-tetrahydroisoquinoline,as a common compound, the synthetic route is as follows.,226942-29-6
To a solution of 6-bromo-l, 2, 3, 4-tetrahydroisoquinoline (400 mg, 1.89 mmol, 1.00 equiv) in tetrahydrofuran (2.00 mL) was added Boc20 (617 mg, 2.83 mmol, 1.50 equiv) and dimethylaminopyridine (46.1 mg, 377 pmol, 0.20 equiv). The mixture was stirred at 25 C for 3 h and was subsequently filtered and concentrated in vacuo to give a residue. The residue was purified by column chromatography (Si02, Petroleum ether/Ethyl acetate = 20/1 to 3/1) to afford tert- butyl 6-bromo-3, 4-dihydro- l //-isoquinoline-2-carboxylate (150 mg, 480 pmol, 25.5% yield) as a white solid. 1H NMR (400MHz, CD3OD) d = 7.38 – 7.32 (m, 2H), 7.07 (d, =8.0 Hz, 1H), 4.52 (br s, 2H), 3.64 (br t, J=6.0 Hz, 2H), 2.84 (t, =6.0 Hz, 2H), 1.51 (s, 9H).
The synthetic route of 226942-29-6 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; MIRATI THERAPEUTICS, INC; MARX, Matthew, Arnold; LEE, Matthew, Randolph; BOBINSKI, Thomas, P.; BURNS, Aaron, Craig; ARORA, Nidhi; CHRISTENSEN, James, Gail; KETCHAM, John, Nichael; (225 pag.)WO2019/152419; (2019); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem